Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 6/20 | 0.44 |
| ▸ | TACR1 | P25103 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LIPE | Q05469 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.34 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6427221 | 0.84 | MAPT (0.38) | POLQMEN1KMT2AKDM4EMAPT | |
| SCHEMBL6498871 | 0.80 | MAPT (0.43) | TACR1MEN1KMT2AMAPTALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL6393605 | 0.79 | POLQ (0.36) | POLQKDM4E | |
| Trifluoroacetic Acid SCHEMBL6507147 | 0.79 | POLQ (0.35) | POLQTACR1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL6426609 | 0.77 | ALDH1A1 (0.57) | TACR1MEN1KMT2AMAPTHTT | |
| SCHEMBL6426785 | 0.77 | MAPT (0.38) | POLQMEN1KMT2AKDM4EMAPT | |
| SCHEMBL6427929 | 0.77 | MEN1 (0.39) | POLQMEN1KMT2AKDM4EMAPT | |
| SCHEMBL6428770 | 0.76 | ALDH1A1 (0.45) | TACR1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL6505144 | 0.75 | TACR1 (0.41) | POLQTACR1MAPTHTTSMN1; SMN2 | |
| SCHEMBL6428317 | 0.75 | PKM (0.40) | POLQMEN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | POLQ 875/4885TACR1 702/4885MEN1 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.